Lumen Bioscience awarded $16.2 million to advance C. difficile treatment
Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.
Stay updated with breaking news from C Difficile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.
Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent Clostridioides difficile (C Diff) infection.
Clostridioides difficile (C difficile) screening in all ICU admissions identified asymptomatic carriers and their risk for developing and/or transmitting infection.
Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing Clostridioides difficile infection.
Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.